|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF320 |
Gene summary for ZNF320 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF320 | Gene ID | 162967 |
| Gene name | zinc finger protein 320 | |
| Gene Alias | ZFPL | |
| Cytomap | 19q13.41 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A2RRD8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 162967 | ZNF320 | HCC1_Meng | Human | Liver | HCC | 1.00e-29 | 5.80e-02 | 0.0246 |
| 162967 | ZNF320 | HCC1 | Human | Liver | HCC | 4.87e-38 | 3.64e+00 | 0.5336 |
| 162967 | ZNF320 | HCC2 | Human | Liver | HCC | 2.50e-54 | 5.08e+00 | 0.5341 |
| 162967 | ZNF320 | HCC5 | Human | Liver | HCC | 4.31e-81 | 4.27e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF320 | MYOFIB | Esophagus | ADJ | ZNF555,HGF,LTC4S, etc. | 0.00e+00 |  |
| ZNF320 | INCAF | Esophagus | ADJ | ZNF555,HGF,LTC4S, etc. | 0.00e+00 | |
| ZNF320 | COR | Oral cavity | NEOLP | WFDC2,AP001505.10,MSLN, etc. | 0.00e+00 |  |
| ZNF320 | BAS | Oral cavity | NEOLP | WFDC2,AP001505.10,MSLN, etc. | 0.00e+00 | |
| ZNF320 | GRA | Oral cavity | NEOLP | WFDC2,AP001505.10,MSLN, etc. | -4.44e-16 | |
| ZNF320 | CD8TRM | Skin | ADJ | CPNE7,EFNB3,ANXA2R, etc. | 8.12e-03 |  |
| ZNF320 | CD8TCM | Skin | ADJ | CPNE7,EFNB3,ANXA2R, etc. | 1.02e-02 | |
| ZNF320 | M1MAC | Skin | AK | CPNE7,EFNB3,ANXA2R, etc. | 1.49e-02 |  |
| ZNF320 | CD8TEXINT | Skin | AK | CPNE7,EFNB3,ANXA2R, etc. | 9.18e-03 | |
| ZNF320 | CD8TRM | Skin | Healthy | CPNE7,EFNB3,ANXA2R, etc. | 1.41e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF320 | SNV | Missense_Mutation | c.1310N>T | p.Gly437Val | p.G437V | A2RRD8 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF320 | SNV | Missense_Mutation | c.257N>C | p.Cys86Ser | p.C86S | A2RRD8 | protein_coding | tolerated(0.23) | benign(0) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
| ZNF320 | SNV | Missense_Mutation | rs770557958 | c.571N>C | p.Cys191Arg | p.C191R | A2RRD8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
| ZNF320 | insertion | Nonsense_Mutation | novel | c.1406_1407insA | p.Tyr469Ter | p.Y469* | A2RRD8 | protein_coding | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | ||
| ZNF320 | SNV | Missense_Mutation | c.526N>T | p.Leu176Phe | p.L176F | A2RRD8 | protein_coding | tolerated(0.06) | benign(0.286) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF320 | SNV | Missense_Mutation | rs765248150 | c.1271G>A | p.Arg424His | p.R424H | A2RRD8 | protein_coding | tolerated(0.43) | benign(0.02) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| ZNF320 | SNV | Missense_Mutation | novel | c.1324N>G | p.Lys442Glu | p.K442E | A2RRD8 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZNF320 | SNV | Missense_Mutation | c.848N>T | p.Ala283Val | p.A283V | A2RRD8 | protein_coding | deleterious(0.04) | benign(0.324) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF320 | SNV | Missense_Mutation | c.1289G>T | p.Arg430Ile | p.R430I | A2RRD8 | protein_coding | tolerated(0.34) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| ZNF320 | SNV | Missense_Mutation | c.1135N>T | p.His379Tyr | p.H379Y | A2RRD8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A02E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |